Why the first Biotech successes will matter more than the biggest ones

In emerging biotech ecosystems, attention often gravitates toward scale. Unicorn valuations and large funding rounds dominate headlines. Yet, in biotechnology, early successes matter more than the biggest ones.

Biotech ecosystems are built on trust. That trust is established through proof of execution, not size. The first companies to navigate development, secure approvals, and reach the market set the tone for future growth.

Early successes validate regulatory processes, manufacturing readiness, and capital alignment. Even modest outcomes signal that the system works.

Chasing scale too early introduces fragility. Large valuations unsupported by execution create pressure and distort incentives.

Saudi Arabia’s biotech ambitions will be shaped by its earliest outcomes. Supporting survivability over spectacle builds credibility.

Early wins attract talent, de-risk capital, and inform policy. They create reference points that compound over time.

Scale follows credibility. Credibility follows execution.

In biotech, staying power creates momentum. The first successes make the biggest ones possible.

• Dr. Huda Alfardus is a businesswoman and biotech investment expert focused on innovation, venture capital, and expanding women’s participation in business and investment markets.